CA2685638C - Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine - Google Patents

Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine Download PDF

Info

Publication number
CA2685638C
CA2685638C CA2685638A CA2685638A CA2685638C CA 2685638 C CA2685638 C CA 2685638C CA 2685638 A CA2685638 A CA 2685638A CA 2685638 A CA2685638 A CA 2685638A CA 2685638 C CA2685638 C CA 2685638C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
metformin
acceptable salt
combination
insulin glargine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2685638A
Other languages
English (en)
Other versions
CA2685638A1 (fr
Inventor
Louise Silvestre
Elisabeth Souhami
Xiaodan Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to CA2685638A priority Critical patent/CA2685638C/fr
Publication of CA2685638A1 publication Critical patent/CA2685638A1/fr
Application granted granted Critical
Publication of CA2685638C publication Critical patent/CA2685638C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une méthode de traitement du diabète sucré de type 2 comprend ladministration de (d) desPro36Exendin-4(1-39)-Lys6-NH2 ou/et un sel pharmaceutiquement acceptable de celui-ci et (e) de linsuline glargine ou/et un sel pharmaceutiquement acceptable de celle-ci et (f) de la metformine ou/et un sel pharmaceutiquement acceptable de celle-ci, à un sujet en ayant besoin.
CA2685638A 2009-11-13 2009-11-13 Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine Active CA2685638C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2685638A CA2685638C (fr) 2009-11-13 2009-11-13 Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2685638A CA2685638C (fr) 2009-11-13 2009-11-13 Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine

Publications (2)

Publication Number Publication Date
CA2685638A1 CA2685638A1 (fr) 2011-05-13
CA2685638C true CA2685638C (fr) 2017-02-28

Family

ID=43989539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2685638A Active CA2685638C (fr) 2009-11-13 2009-11-13 Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine

Country Status (1)

Country Link
CA (1) CA2685638C (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
EP3229828B1 (fr) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Also Published As

Publication number Publication date
CA2685638A1 (fr) 2011-05-13

Similar Documents

Publication Publication Date Title
EP2329848B1 (fr) Lixisénatide en tant que traitement d'appoint à l'insuline glargine et à la metformine dans le diabète de type 2
US20110118178A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
DK2324853T3 (en) Lixisenatide as an add-on to metformin to treat diabetes type 2
US20110118180A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
JP6676108B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
DK2750699T3 (en) A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
DK3010530T3 (en) FIXED-FORMULATED FORMULATION BETWEEN INSULIN GLARGIN AND LIXISENATIDE
US20240173384A1 (en) Treatment of pediatric type 2 diabetes mellitus patients
TWI748945B (zh) 第２型糖尿病病患治療
US20250319163A1 (en) Treatment of type 2 diabetes mellitus
CA2685638C (fr) Methode concue pour traiter le diabete de type 2 comprenant un traitement d'appoint par l'insuline glargine et la metformine
JP5980466B2 (ja) インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法
KR20110052990A (ko) 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
AU2009238271B2 (en) Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
MX2009012308A (es) Metodo de tratamiento de diabetes tipo 2 que comprende terapia de adicion a insulina glargina y metformina.
CA2685636C (fr) Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine
AU2009238272A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
JP2011105609A (ja) メトホルミンへの付加療法を含む２型糖尿病の治療方法
BRPI0904428A2 (pt) método de tratamento de diabetes do tipo 2 compreendendo terapia adjuvante à insulina glargina e metformina
MX2009012310A (es) Metodo de tratamiento de diabetes tipo 2 que comprende terapia de adicion a metformina.
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
Gallwitz What should be the second-line therapy after metformin in the overweight type 2 diabetic patient?
BR112017018388B1 (pt) Uso de combinação farmacêutica para o controle da glicemia em indivíduo com diabetes mellitus tipo 2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241029

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241029

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241029

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251021

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251021